Persistent Pulmonary Hypertension of the Newborn and Selective Serotonin Reuptake Inhibitors: Lessons From Clinical and Translational Studies
ABSTRACT Two recent studies linking in utero exposure to selective serotonin reuptake inhibitors (SSRIs) with persistent pulmonary hypertension of the newborn (PPHN), a potentially serious but rare respiratory illness, have made clinicians and patients more reluctant to use SSRIs during pregnancy. However, additional clinical studies have associated maternal depression rather than SSRI exposure as a risk factor for PPHN. This review summarizes the current knowledge regarding PPHN pathophysiology, including the role of serotonin and genetic risk factors; the effects of SSRIs on pulmonary vasculature; the possible link between SSRIs and PPHN; and the diagnosis, clinical management, and prognosis of PPHN.
- American Journal of Psychiatry 02/2012; 169(2):121-4. DOI:10.1176/appi.ajp.2011.11111622 · 13.56 Impact Factor
Article: [Pain medication during pregnancy].[Show abstract] [Hide abstract]
ABSTRACT: To treat pain that does not respond to non-pharmacological approaches in a pregnant woman represents a challenge for the primary care physician. He is often the first health professional to be consulted and finds himself confronted to not only one but two patients:the motherand the fetus. His knowledge on pain treatment and the practical approach that he is used to, will have to be adapted to this new equation. He will have to weigh the benefit for the mother against the risk for the fetus, while creating a true relationship with his patient. Although only a few drugs are considered compatible with pregnancy, the data available from the literature allow nowadays to better understand the nature of the risk when exposing the fetus to a given drug and to elaborate evidence-based recommendations.Revue médicale suisse 06/2012; 8(347):1389-92, 1394.
- [Show abstract] [Hide abstract]
ABSTRACT: Persistent pulmonary hypertension of the newborn (PPHN) is a rare but potentially life-threatening neonatal condition. Several authors have suggested that late pregnancy exposure to selective serotonin reuptake inhibitors (SSRIs) may increase the risk of PPHN. This association has been investigated in seven published studies that have shown mixed findings based on diverse methods. Several methodological limitations may account for the diversity of findings, which include, in some studies, a lack of control for well established risk factors for PPHN. The methodological improvement in the most recent study tentatively suggests that infants prenatally exposed to SSRIs are approximately twice as likely to suffer PPHN. Further research on the biological mechanisms involved is required. Clinicians should consider late pregnancy exposure to SSRIs as one of several possible risks for PPHN, which has implications for both prescribing SSRIs to pregnant women and for neonatal care of SSRI-exposed infants.CNS Drugs 10/2012; 26(10):813-22. DOI:10.2165/11630310-000000000-00000 · 4.38 Impact Factor